Medical Radiology and Radiation Safety. 2025. Vol. 70. № 4
DOI:10.33266/1024-6177-2025-70-4-106-110
A.V. Muravleva1, 3, V.I. Chernov1, 2, V.E. Goldberg1, E.A. Shamsimukhametova1,
R.V. Zelchan1, 2, A.A. Medvedeva1, 2, O.D. Bragina1, 2, N.O. Popova1,
V.V. Vysotskaya1, A.N. Rybina1, A.V. Goldberg1
SPECT/CT with 99mTc-PSMA in the Staging and Diagnosis of Hodgkin Lymphoma
1 Tomsk National Research Medical Center, Tomsk, Russia
2 National Research Tomsk Polytechnic University, Tomsk, Russia
3 Siberian State Medical University, Tomsk, Russia
Contact person: A.V. Muravleva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: Demonstrate the possibility of using 99mTc-PSMA SPECT/CT to visualize Hodgkin’s lymphoma at the diagnostic stage, as well as during therapy.
Material and methods: The patient diagnosed with Hodgkin’s lymphoma underwent standard studies – computed tomography with intravenous contrast, as well as PET/CT with 18F-FDG. Additionally, 99mTc-PSMA SPECT/CT was performed.
Results: A clinical case of Hodgkin’s lymphoma with mediastinal lesions in a young patient is described. The possibility of modern nuclear medicine methods in the diagnosis of Hodgkin’s lymphoma is demonstrated. SPECT/CT with 99mTc-PSMA was performed as an alternative diagnostic method when it is impossible to perform PET/CT with 18F-FDG at the stage of specific treatment.
Conclusion: The article presents a clinical case of Hodgkin’s lymphoma with mediastinal involvement in a young patient. The capabilities of SPECT/CT with 99mTc-PSMA for visualization of mediastinal lesions was demonstrated.
Keywords: Hodgkin’s lymphoma, prostate-specific membrane antigen, SPECT/CT, 99mTc-PSMA
For citation: Muravleva AV, Chernov VI, Goldberg VE, Shamsimukhametova EA, Zelchan RV, Medvedeva AA, Bragina OD, Popova NO, Vysotskaya VV, Rybina AN, Goldberg AV. SPECT/CT with 99mTc-PSMA in the Staging and Diagnosis of Hodgkin Lymphoma. Medical Radiology and Radiation Safety. 2025;70(4):106–110. (In Russian). DOI:10.33266/1024-6177-2025-70-4-106-110
References
1. Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Zlokachestvennykh Limfoproliferativnykh Zabolevaniy = Russian Clinical Guidelines for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Samara Publ., 2018. 470 p. (In Russ.).
2. Salas Fragomeni R.A., Amir T., Sheikhbahaei S., Harvey S.C., Javadi M.S., Solnes L.B., et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018;59;6:871-7. doi: 10.2967/jnumed.117.203570.
3. Al-Ahmadie H.A., Olgac S., Gregor P.D., Tickoo S.K., Fine S.W., Kondagunta G.V., et al. Expression of Prostate-Specific Membrane Antigen in Renal Cortical Tumors. Mod Pathol. 2008;21;6:727-32. doi: 10.1038/modpathol.2008.42.
4. Wang J.H., Kiess A.P. PSMA-Targeted Therapy for Non-Prostate Cancers. Front Oncol. 2023 Aug 14;13:1220586. doi: 10.3389/fonc.2023.1220586. PMID: 37645427. PMCID: PMC10461313.
5. Chernov V.I., Dudnikova Ye.A., Gol’dberg V.Ye., Kravchuk T.L., Danilova A.V., Zel’chan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.D., Popova N.O., Gol’dberg A.V. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphoproliferative Diseases. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2018;63;6:41-50 (In Russ.).
6. Barrington S.F., Mikhaeel N.G., Kostakoglu L., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58. doi: 10.1200/JCO.2013.53.5229.
7. Cheson B.D., Fisher R.I., Barrington S.F., et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: the Lugano Classification. J Clin Oncol. 2014;32:3059-68. doi: 10.1200/JCO.2013.54.8800.
8. Dreyling M., Thieblemont C., Gallamini A., et al. ESMO Consensus Conferences: Guidelines on Malignant Lymphoma. Part 2: Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma. Ann Oncol. 2013;24:857–77. doi: 10.1093/annonc/mds643.
9. Boellaard R., Delgado-Bolton R., Oyen W.J.G., et al. FDG PET/CT: EANM Procedure Guidelines for Tumour Imaging: Version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354.
10. Zeltchan R., Medvedeva A., Sinilkin I., et al. Experimental Study of Radiopharmaceuticals Based on Technetium-99m Labeled Derivative of Glucose for Tumor Diagnosis. VIII International Scientific Conference Issues of Physics and Technology in Science, Industry and Medicine. Tomsk, 1–3 June, 2016. IOP Conference Series: Materials Science and Engineering. 2016;135:012054. doi. 10.1088/1757-899X/135/1/012054.
11. Zel’chan R.V., Medvedeva A.A., Sinilkin I.G., et al. Study of the Functional Suitability of the Tumorotropic Radiopharmaceutical 99mTc-1-thio-D-glucose in an Experiment. Molekulyarnaya Meditsina = Molecular Medicine. 2018;16;2:54-57 (In Russ.). doi: 10.29296/24999490-201803-11
12. Chernov V.I., Medvedeva A.A., Sinilkin I.G., et al. Development of Radiopharmaceuticals for Radionuclide Diagnostics in Oncology. Meditsinskaya Vizualizatsiya = Medical Visualization. 2016;2:63-66 (In Russ.).
13. Chernov V.I., Dudnikova E.A., Zelchan R.V., et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Siberian Oncology Journal. 2018;17;4:81-87. doi: 10.21294/1814-4861-2018-17-4-81-87.
14. Dudnikova Ye.A., Chernov V.I., Muravleva A.V., et al. Metabolic Single-Photon Emission Computed Tomography with a new Radiopharmaceutical Drug «99mTc-1-thio-D-glucose» in the Diagnosis and Monitoring of Isolated Breast Lymphoma (Clinical Observation). Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2020;19;5:145-153 (In Russ.). doi: 10.21294/1814-4861-2020-19-5-145-153.
15. Muravleva A.V., Chernov V.I., Dudnikova Ye.A., et al. Metabolic Single-Photon Emission Computed Tomography with “99mTc-1-thio-d-glucose” - New Possibilities for Staging Hodgkin’s Lymphoma. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiation Diagnostics. 2021;11;3:171-177 (In Russ.). doi: 10.21569/2222-7415-2021-11-3-171-177.
16. Chernov V., Dudnikova E., Zelchan R., Medvedeva A., Rybina A., Bragina O., Goldberg V., Muravleva A., Sörensen J., Tolmachev V. Phase I Clinical Trial Using [99mTc]Tc-1-Thio-D-Glucose for Diagnosis of Lymphoma Patients. Pharmaceutics. 2022;14:1274.
17. Tolmachev V.M., Chernov V.I., Deyev S.M. Targeted Nuclear Medicine. See and Destroy. Russ Chem Rev. 2022;91:RCR5034 (In Russ.). doi: 10.1070/RCR5034.
18. Chernov V.I. Innovative Radiopharmaceuticals in Diagnostics and Radionuclide Therapy of Malignant Neoplasms. Vestnik Rossiyskoy Akademii Nauk = Bulletin of the Russian Academy of Sciences. 2024;94;1:66-79 (In Russ.). doi: 10.31857/S0869587324010088.
19. Lishmanov Yu.B., Chernov V.I., Krivonogov N.G., Glukhov G.G., Maslova L.V. Perfusion Scintigraphy of the Myocardium with 199Tl-Chloride in the Experiment. Meditsinskaya Radiologiya = Medical Radiology. 1988;33;3:13-16 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out with the financial support of the transport hub development program «Priority 2030» (Priority-2030-IZ-024-
202-2024).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.03.2025. Accepted for publication: 25.04.2025.